1365170-20-2 Usage
General Description
1-(Bicyclo[3,1,0]hexan-3-yl)-6-(methylsulfonyl)-1H-pyrazolo[3,4-d]pyrimidine is a compound with a complex structure and a number of potentially important chemical properties. It contains a bicyclo[3,1,0]hexane ring system, a sulfonyl group, and a pyrazolo[3,4-d]pyrimidine ring. The bicyclo[3,1,0]hexane ring system is a fused bicyclic system that can have interesting steric and electronic effects. The sulfonyl group, which consists of a sulfur atom double-bonded to two oxygen atoms, is known for its electron-withdrawing properties, which can affect the reactivity of the molecule. The pyrazolo[3,4-d]pyrimidine ring is a fused heterocyclic system that can have biological and pharmacological significance. These structural features make 1-(Bicyclo[3,1,0]hexan-3-yl)-6-(methylsulfonyl)-1H-pyrazolo[3,4-d]pyrimidine an interesting target for further chemical, biological, and pharmacological investigations.
Check Digit Verification of cas no
The CAS Registry Mumber 1365170-20-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,5,1,7 and 0 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1365170-20:
(9*1)+(8*3)+(7*6)+(6*5)+(5*1)+(4*7)+(3*0)+(2*2)+(1*0)=142
142 % 10 = 2
So 1365170-20-2 is a valid CAS Registry Number.
1365170-20-2Relevant articles and documents
Synthesis, SAR and biological evaluation of 1,6-disubstituted-1H- pyrazolo[3,4-d]pyrimidines as dual inhibitors of Aurora kinases and CDK1
Le Brazidec, Jean-Yves,Pasis, Angela,Tam, Betty,Boykin, Christina,Black, Cheryl,Wang, Deping,Claassen, Gisela,Chong, Jer-Hong,Chao, Jianhua,Fan, Junhua,Nguyen, Khanh,Silvian, Laura,Ling, Leona,Zhang, Lin,Choi, Michael,Teng, Min,Pathan, Nuzhat,Zhao, Shuo,Li, Tony,Taveras, Art
, p. 2070 - 2074 (2012/04/23)
Since the early 2000s, the Aurora kinases have become major targets of oncology drug discovery particularly Aurora-A and Aurora-B kinases (AKA/AKB) for which the selective inhibition in cells lead to different phenotypes. In addition to targeting these Aurora kinases involved in mitosis, CDK1 has been added as a primary inhibition target in hopes of enhancing the cytotoxicity of our chemotypes harboring the pyrazolopyrimidine core. SAR optimization of this series using the AKA, AKB and CDK1 biochemical assays led to the discovery of the compound 7h which combines strong potency against the 3 kinases with an acceptable microsomal stability. Finally, switching from a primary amide to a two-substituted pyrrolidine amide gave rise to compound 15a which exhibited the desired AKA/CDK1 inhibition phenotype in cells but showed moderate activity in animal models using HCT116 tumor cell lines.
